Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Myron David Kor who wrote (866)	11/22/1997 1:51:00 PM
From: Cacaito	Respond to of 7041

Myron, if one publishes in the Lancet, the NEJM or in many others prestigious journals there are plenty of data (not all of course)to have a good understanding of the drug and the editorials are always asking for more details and the readers'letters are full of complains or praise and again asking for more details which are many times given, or explained in responses by the authors. If one reads today's IBD they mentioned in their Ethical drug industry review that an FDA application could be as long as 100,000 pages (this could not be fit in a 3 to 4 pages journal article). I will like to see "some" data from Zonagen or Pfizer. It is a matter of fairness to investors. I could understand that for trade secrets they will hold lots of data, but I will not invest in them. Are the roadshows to big institutions for the purpose of providing then with information and data? Small investors have sustained this company from the beggining, Will you drop your support if they give you the same advantageous information? Will they get lets money in their 2ry offering? I doubt that this company has strong followers. I could see the accumulation in the technicals rebounding just because of Podolsky's talk, which offered nothing new, just repetition. It is not fair that small investors do not have access to even "some" data. I was not happy at all when Podolsky said "there is an advantage in being second" to the question of delayed FDA approval and PFE going first ahead. Not even the type II German studies (couple of years old) or the Mexican III studies (a year old?) are out. The American III studies are not out (several months old). Small struggling biotechs do publish to garnish support. Zonagen has being able to raise more than $100 million just because we (I was a Zonagen investor after the Mexican studies Pr news) plainly believe in then. I do see that they do not have to publish anything because they did accomplished what others accomplished by giving information and data away. In that sense, there is no advantage to Zonagen. But there is an advantage to the investors, at least the ones who could not be present in the road shows (unless BigKNY3 believes in the fairness of us investing by faith, and they investing by fact). And if the company is to keep the stock price up, there is only one way, to provide the information on the data before FDA submission which is at least months to a year ahead (they have to finish the actual ongoing study), before approval 1-2 years ahead, and before sales.... years ahead. I do not even believe that Schering is giving the $10 millions without any protection for their money, the full financial agreement is like the science data not out, one could read it clearly in the pr release.